Healthcare AI's Next Phase: Hyro Bets Big on Seasoned Leadership

NEW YORK, NY – July 29, 2026 – In a move that signals a broader maturation in the healthcare technology market, Agentic Care Communications platform Hyro has fortified its leadership team, appointing Brant Castellow as Chief Revenue Officer and Yehuda Berkowitz as VP of Sales Development. While executive appointments are routine, these hires represent more than just a personnel update; they are a calculated maneuver to capitalize on a critical inflection point for artificial intelligence in healthcare—the transition from tentative pilots to indispensable infrastructure.

For years, health systems have cautiously experimented with AI, but the industry is now witnessing a decisive shift. The announcement from Hyro, a company whose platform has already managed over 100 million patient conversations, underscores that the era of AI merely 'demoing well' is over. The new imperative is to scale, integrate, and deliver measurable value within the most critical, complex, and regulated workflows in medicine. The addition of Castellow and Berkowitz is Hyro's high-stakes bet that it has the right technology and, now, the right commercial leadership to dominate this new phase.

The End of the AI Pilot Era

The demand for agentic AI in healthcare is no longer speculative; it's explosive. Market projections show a sector poised for staggering growth, with some analysts forecasting a market size of nearly $5 billion by 2030, reflecting a compound annual growth rate (CAGR) exceeding 45%. This surge isn't driven by novelty but by necessity. Plagued by chronic staffing shortages and immense administrative burdens, health systems are turning to technology not just for efficiency, but for survival.

Unlike earlier chatbots or simple automation tools, agentic AI represents a significant leap. These are systems designed to plan, decide, and act autonomously to achieve goals. For a company like Hyro, this means its AI agents don't just route calls; they resolve patient requests end-to-end by integrating directly into a hospital's core Electronic Health Record (EHR) and telephony systems. This allows for the complete automation of complex tasks like scheduling appointments, processing registrations, and handling prescription refills—a level of capability that was once the domain of science fiction.

According to recent industry reports, over 80% of health systems are now prioritizing agentic AI for everything from clinical operations to revenue cycle management. The technology is seen as essential for alleviating the pressure on overstretched staff and improving the patient experience. As Hyro's CEO Israel Krush noted, "Health systems are no longer asking whether agentic AI belongs in patient care. They're putting it to work in their most critical interactions, and that raises the bar for every partner they choose."

Assembling the Go-to-Market Engine

This heightened bar is precisely where Brant Castellow and Yehuda Berkowitz enter the picture. Selling sophisticated, mission-critical AI into the risk-averse healthcare sector requires more than a compelling product; it requires a deeply experienced human touch, a repeatable process, and an unwavering focus on building trust. Hyro's leadership expansion is a clear acknowledgment of this reality.

Castellow, the new CRO, brings a formidable 25-year track record in healthcare technology sales. His recent tenure at Reveleer saw him help grow the company's annual recurring revenue by six times, a feat achieved by building and scaling an enterprise go-to-market organization through a period of rapid expansion. His career includes leadership roles at industry giants like Cerner, demonstrating an innate understanding of how to navigate the complex procurement cycles of large health systems. "What drew me to Hyro is what the team has created: AI agents, purpose-built for healthcare, that take action," Castellow stated, emphasizing the platform's ability to resolve tasks rather than just route them. His focus will be on deepening relationships with existing clients, expanding into new service lines, and pushing into the mid-market.

Complementing Castellow's enterprise expertise is Yehuda Berkowitz, who is tasked with building a predictable pipeline engine. At previous high-growth companies like DealHub and AppsFlyer, Berkowitz architected sales development functions that generated hundreds of millions in pipeline. His philosophy is clear: "Systems beat heroics." In a market where demand is climbing fast, his role is to ensure growth is predictable, not lucky, by aligning marketing, sales development, and customer success around a single, scalable playbook. "Repeatable results come when marketing, sales development, and customer success all run from the same playbook, and building that is what drew me here," Berkowitz said.

The Hidden Costs of Scaling

While the opportunity is immense, the path to scaling AI in healthcare is fraught with peril. The 'hidden cost' of rapid technological adoption in this sector is the potential for eroding the very trust it aims to build. A poorly implemented AI agent that mishandles a patient's appointment request or provides incorrect information doesn't just create a poor customer experience—it can have direct clinical and financial repercussions. This is the central challenge that Hyro, and its new leadership, must navigate.

Krush himself acknowledged this delicate balance, noting the goal is to add leaders who "know how to turn momentum into lasting infrastructure: the people, the pipeline, and the workflows that scale a company without eroding trust." Castellow echoed this, stating his desire for Hyro's go-to-market motion to be judged by the same standard as its AI agents: "by the quality of the experience it creates for the customer."

This focus on trust and quality is a critical differentiator in a crowded market. Competitors ranging from enterprise giants like Oracle and ServiceNow to specialized players like Kore.ai and Hippocratic AI are all vying for a piece of the healthcare AI pie. Success will not be determined by the most advanced algorithm alone, but by the ability to deploy that algorithm safely, reliably, and at scale, with a commercial process that inspires confidence rather than creates friction.

From Conversations to Intelligence

Hyro's strategy extends beyond simple automation. The company's recent launch of its "Care Intelligence" platform signals a move up the value chain, aiming to transform the millions of patient conversations it handles from transactional data into strategic insights. By analyzing interaction data, the platform can help health systems identify shifts in patient demand, pinpoint access breakdowns, and uncover the root causes of patient drop-off. This positions the company not merely as a vendor of AI agents, but as a strategic partner in optimizing care access and operational performance.

This combination of end-to-end automation and deep analytical insight is what Hyro is betting will solidify its leadership position. The recent addition of Dr. Sindhu Pandit as VP of Clinical Product Strategy, followed now by the commercial leadership of Castellow and Berkowitz, completes a strategic triad designed to align a clinically-sound product with a powerful and trustworthy go-to-market engine. Together, they are tasked with helping Hyro define its next phase of growth by carrying its platform to more health systems, expanding access to care while easing the immense pressure on healthcare staff.